Inflammatory bowel disease (IBD) therapy often requires biologic medications delivered by intravenous infusion.1-4 Historically, intravenous infusions of infliximab and vedolizumab in patients with IBD were delivered under direct supervision of clinicians in infusion centers at hospitals or clinics. Recently, intravenous infusions have transitioned into patient homes. Professional societies have differed on their recommendations for biologic home infusions (HI),5,6 yet limited data exist on the safety and efficacy of HI programs.7,8 Therefore, the primary aim of this study was to compare adverse outcomes (AOs), as defined as a composite of stopping therapy, IBD-related emergency-room (ER) visit, or IBD-related hospitalization, in patients with IBD receiving biologics as HI or at a hospital-based infusion center.

Original languageEnglish
Pages (from-to)257-258
Number of pages2
JournalClinical Gastroenterology and Hepatology
Issue number1
StatePublished - Jan 2020


Dive into the research topics of 'Home vs Hospital Infusion of Biologic Agents for Patients With Inflammatory Bowel Diseases'. Together they form a unique fingerprint.

Cite this